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Abstract: The approach of the European Medicines Agency (EMA) to the transparency 
of the documents submitted by the pharmaceutical enterprises has evolved significantly during 
the last decade. The gradual development of the EU’s secondary legislation, namely the adoption 
of EMA Policy on access to documents (Policy 0043, 2010) followed by the Policy on 
publication of clinical data (Policy 0070, 2014) and Clinical Trials Regulation No 536/2014 have 
raised more issues as they arguably question the substance of the ‘commercially confidential 
information’ notion. The ongoing public health crisis seems to have fuelled the discourse, in 
view of the EMA calls to urge transparency and collaboration on COVID-19 studies - to 
facilitate more robust research results. Even though the first attempts were made to investigate 
the CJEU’s approach to the application of the EMA Policies 0043 and 0070, a very important 
issue - namely, the impact of the EU Charter on the EMA transparency policies - comprising the 
extra transparency measures for COVID-19 vaccines and therapeutics – still remains unsolved. 
Considering the InterMune UK, PTC Therapeutics International, MSD Animal Health 
Innovation lines of reasoning, this paper aims to explore if and how the EU Court of Justice 
applies relevant CFREU provisions, in order to counter-balance the competing interests of the 
pharma enterpises (confidentiality of the clinical data) and the European Medicines Agency 
(public access to the documents). The main argument presented is that the CJEU’s approach to 
Art. 7 (‘Respect for private and family life’) and – sporadically – Arts. 16 (‘Freedom to conduc t 
a business’), 17 (‘Right to property’) and 47 (‘Right to an effective remedy and to a fair trial’) 
CFREU in these cases has manifested the transition from the general presumption of 
confidentiality with respect to the company-issued health data to disclosure of such data - with a 
low likelyhood of changes in the observable future, even in view of the ongoing COVID-2019 
developments. 
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i. Introduction. The European Medicines Agency (further - EMA) is the European Union 
(further - EU) body responsible for the scientific evaluation, issue of the centralised marketing 
authorisation (further - MA) applications and supervision of medicinal products for human and 
veterinary use. The EMA is responsible for granting approval for effective and safe medicinal 
products in the form of MA and – indirectly - harmonising research procedures in the EU, in 
particular through collecting the clinical trials data (further - CTD) submitted as a part of the MA 
application dossier.1 Importantly, the EMA decisions are subjected to a judicial review of the 
Court of Justice of the European Union (further – CJEU) pursuant to Art. 263(1) of the Treaty on 
the Functioning of the European Union (further – TFEU)2 and any arbitration clause contained in 
a contract concluded by the Agency. 3  
As of its establishment the EMA has embraced openness of operation as an important 
feature: Art. 73 of Regulation (EC) No. 726/2004 prominently declared that the key Regulation 
(EC) No. 1049/2001 regarding public access to European Parliament, Council and Commission 
documents shall apply to the Agency as well.4 Only few exceptions shall be applicable in this 
regard - such as, for instance, the overriding public policy concerns (public security, defence and 
military matters, international relations etc.), the protection of personal data, or the commercial 
interests of a natural or legal person including the protection of the so-called ‘commercially 
confidential information’ (furthermore: CCI).5  
The Treaty of Lisbon favored further development of the openness, transparency and the 
right to access documents in EU Law. For instance, Art. 15 TFEU obliged the EU’s legislature to 
act publicly, and established that citizens shall have the right to access documents held by all 
Union institutions, bodies and agencies. Moreover, the right of access to documents, and its 
nature as a fundamental right, is further emphasised by Art. 42 of the Charter of Fundamental 
                                                             
1 Daria Kim, ‘Transparency Policies of the European Medicines Agency: Has the Paradigm Shifted? ’ 
[2017] 25(3) Oxford Medical Law Review 456, 457. 
 2 Art. 263(1) TFEU [The Court of Justice] shall also review the legality of acts of bo dies, offices or 
agencies of the Union intended to produce legal effects vis-à-vis third parties. 
3 In this sense, see for example Case C-513/16 P(R) European Medicines Agency (EMA) v. PTC 
Therapeutics International Ltd, or Regulation No. 726/2004 laying down Community procedures for the 
authorisation and supervision of medicinal products for human and veterinary use and es tablis hing a European  
Medicines Agency, Art. 72(1). 
4 Regulation (EC) No 726/2004 of the European Parliament and of the Council laying down Community 
procedures for the authorisation and supervision of medicinal products for human and veterinary use and 
establishing a European Medicines Agency [2004] OJ L 136. 
5 Regulation (EC) No 1049/2001 of the European Parliament and of the Council regarding public access to  
European Parliament, Council and Commission documents [2001] OJ L 145, Art. 4. 
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Rights of the European Union (CFREU), which is now of ‘the same legal value as the Treaties’.6 
It could be argued that the approach of the European Medicines Agency to the transparency of 
the documents submitted by the pharmaceutical enterprises, has itself evolved significantly 
during the last decade – one of the main reasons for these changes was the growing impact of the 
European Ombudsman on the European Agencies, including the EMA.  
In 2010, Mrs. Emily O’Reily delivered a number of decisions that were critical of the 
EMA approach, including one relating to clinical study reports.7 In particular, she mentioned the 
limited access of the EU public to the Agency documents which did not seem to be consistent 
with the overriding interest in providing sufficient information to the healthcare professionals 
and patients.8 However, the follow-up development of the EU’s secondary legislation, namely 
the adoption of EMA Policy on access to documents (Policy 0043, 2010) followed by the Policy 
on publication of clinical data (Policy 0070, 2014) and Clinical Trials Regulation No 536/2014 
has raised more issues as they arguably question the substance of the notion ‘commercially 
confidential information’ (i.e. the information which shall be excluded from public access within 
the given context, as the disclosure may undermine the legitimate economic interest of the 
enterprise). Since autumn 2016, the European Medicies Agency published the clinical reports 
submitted under the centralized marketing authorization procedure once the procedure has been 
finalized. Prior to this, EMA only released clinical-trial reports on request and treated documents 
in marketing authorization files as generally confidential (Policy 0043).9  
Even though the European Medicines Agency temporarily suspended the publication of 
clinical data on December 5, 2018 as a result of the implementation of the third phase of EMA’s 
business continuity plan due to Brexit and the headquarter’s move to Amsterdam,10  the Agency 
has reinitiated this activity specifically for COVID-19 medicines in line with its exceptional 
transparency measures for treatments and vaccines for this desease .11 Hence, the issue of 
balancing the business interests of enterprises and the need to make the EMA activities 
transparent for the EU patients becomes remains extremely pertinent, considering high costs of 
research and revelopment in pharmacological sector. Bearing in mind these premises, it could be 
expected from the pharma enterprises to oppose this developing ‘pro-transparency’ trend, by 
                                                             
6 Charter of Fundamental Rights of the European Union [2012] OJ C 326.  
7 Decision of the European Ombudsman closing his inquiry into complaint 2560/2007/BEH against the 
European Medicines Agency (The European Ombudsman Official Website, 2010). Available at 
https://www.ombudsman.europa.eu/en/decision/en/5459, 10 June 2019. 
8 Ibid., paras. 34, 35, 47. 
9 Elisa Stefanini, ‘Publication of Clinical Trials Data: A New Approach to Transparency in  the European 
Legislative Framework’ [2017] 1(1) Medicine Access: Point of Care 98, 99. 
10 Response to ASK-74893 - EMA transparency policies in light of COVID 19, received on 10 December 
2020, p. 3. 
11 Ibid., p. 4. 
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putting forward the Fundamental Rights-centered argumentation in dialogue with the European 
Medicines Agency.12  
Even though the first attempts were made to investigate the CJEU’s approach to the 
application of the EMA Policies 0043 and 0070, a very important issue - namely, the impact of 
the EU Charter on the EMA transparency policies - comprising the extra transparency measures 
for COVID-19 vaccines and therapeutics – still remains unsolved. In view of the InterMune UK, 
PTC Therapeutics International, MSD Animal Health Innovation lines of reasoning, this paper 
aims to explore if and how the EU Court of Justice applies relevant CFREU provisions in cases 
involving the European Medicies Agency transparency policies. Then, the working paper sheds 
light on the developments in the EMA transparency policies related to the COVID-19 crisis, 
investigating if the EU Charter had any influence on the development of the Agency dialogue 
with the EU wide public and pharmaceutical enterprises. 
To illustrate these developments, firstly, an attempt is made to analyse the scope of 
protection of the ‘commercially confidential information’ within the context of the EMA 
activities afforded by the Transparency, Authorisation and Clinical Trials Regulations, as well as 
by the EMA Policies 0043 and 0070.  Secondly, this paper elaborates on existing CJEU case-law 
with the CFREU component which creates a legal framework for the implementation of the 
abovementioned legal acts (AbbVie/InterMune, PTC Therapeutics International, Pari Pharma, 
MSD Animal Health Innovation). Thirdly, the paper probes the reasoning adopted by the 
European Medicines Agency, European Ombudsman and the members of the research 
community in course of the development of the EMA COVID-related transparency policies, and 
sheds light on the authorisation strategy for the Coronavirus vaccines and therapeutics - 
considering the feedback received from the European Medicines Agency.13 
The main argument presented is that the CJEU’s approach to Art. 7 (‘Respect for private 
and family life’) and – sporadically – Arts. 16 (‘Freedom to conduct a business’), 17 (‘ Right to 
property’) and 47 (‘Right to an effective remedy and to a fair trial’) CFREU in these cases has 
manifested the transition from the general presumption of confidentiality with respect to the 
company-issued health data to disclosure of such data. This narrative could be presumably 
explained by the prevailing interest in protecting public health and fostering the innovation 
capacity of European medical research - with a low likelyhood of changes in the observable 
future, even in view of the ongoing COVID-2019 developments.  
  
                                                             
12 Daria Kim, ‘Transparency Policies of the European Medicines Agency: Has the Paradigm Shifted? ’ 
[2017] 25(3) Oxford Medical Law Review 456, 459. 





1. The EMA ‘transparency policies’ vs. CCI: the scope of protection 
 Before moving on to the disussion on the substance of the EMA pertinent Policies 
0043/0070 in light of the fundamental rights concerns of the farmaceutical enterprises, it could 
be necessary to shed light on the pertinent EU primary law provisions. The definition of the 
notion of the commercially confidential information shall be interpreted in light of Art. 15(3) 
TFEU which extends the public right of access to documents of all the Union institutions, bodies, 
offices and agencies. Despite an evident added value of this provision as a tool to enhance the 
democratic legitimacy of the European institutions through the involvement of the EU 
individuals, the application of this provision is – by its nature – rather problematic. On one hand, 
the EMA shall take into account such factors as the need to inform the public, protect public 
health effectively and foster the innovation capacity of European medical research. On the other 
hand, the Agency must consider the business interests of pharmaceutical enterprises – given the 
lack of general regulation or the classification of ‘sensitive’ documents in the EU, and the lack of 
the general mechanism of guaranteeing transparency in that field.14 
a) The EU’s secondary law. The basic Regulation No 1049/2001 regarding public access 
to European Parliament, Council and Commission documents provides a very broad definition of 
the EU ‘document’ which shall be disclosed to the public as ‘any content whatever its medium 
(written on paper or stored in electronic form or as a sound, visual or audiovisual recording) 
concerning a matter relating to the policies, activities and decisions falling within the 
institution’s sphere of responsibility’ (Art. 3(a)). The limitations imposed on the general rule of 
access could be justified by the considerations of the public interest (Art. 4(1)a), privacy and the 
integrity of the individual (4(1)b), protection of commercial  interests of the individuals and/or 
the enterprises (Art. 4(2)), or/and the effectiveness of the EU institution’s decision-making 
process (Art. 4(3)).  
These exceptions shall generally apply for the period during which protection is justified 
on the basis of the content of the document (and for a maximum period of 30 years), even though 
in the case of documents covered by the exceptions relating to privacy or commercial interests 
the exceptions may, if necessary, continue to apply after this period.15 Moreover, Art. 4(2) 
prominently offers an additional stage in assessing the proportionality of the limitations in cases 
involving the commercial interests of the enterprises: the documents which are normally entitled 
                                                             
14 Henri Labayle, ‘Principles and procedures for dealing with European Union Classified  In format ion in  
light of the Lisbon Treaty’ (European Parliament Official Website, 2010). Available at 
http://www.europarl.europa.eu/document/activities/cont/201006/20100601ATT75403/20100601ATT75403EN.pdf, 
accessed 10 January 2021. 
15 Regulation (EC) No 1049/2001 of the European Parliament and of the Council regarding public access to 
European Parliament, Council and Commission documents [2001] OJ L 145, Art. 4(7). 
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to the non-disclosure, still could be made accessible to the public, in case of the ‘overriding 
public interest in disclosure’.  
This very general legal framework defined a need to frame institution-specific rules for 
the public access procedures and – subsequently – detailed rules on the pertient exceptions for 
the information which shall be excluded from such an access, in view of the Art. 4(2) clause of 
Regulation No. 1049/2001 (‘commercial interests of a natural or legal person, including 
intellectual property rights’). Regulation No. 1049/2001 on access to the EU documents was 
primarily drafted to be applicable only to the European Parliament, the Council, and the 
Commission. However, its application to the EMA activities was extended by virtue of a specific 
clause in Regulation (EC) No 726/2004, laying down Community procedures for the 
authorisation and supervision of medicinal products for human and veterinary use and 
establishing a European Medicines Agency (‘The Authorisation Regulation’): 
 ‘... Article 73 (1). Regulation (EC) No. 1049/2001 of the European Parliament and of the 
Council of 30 May 2001 regarding public access to European Parliament, Council and 
Commission documents (1) shall apply to documents held by the Agency.  
Article 73 (1). The Agency shall set up a register pursuant to Article 2(4) of Regulation 
(EC) No 1049/2001 to make available all documents that are publicly accessible pursuant to this 
Regulation’. 
Art. 57(l) of Regulation (EC) No. 726/2004 specifies the form in which the information 
shall be made availiable to public: the EMA shall run a database (‘Eudravigilance database’) on 
medicinal products which have already obtained a marketing authorisation, which is accessible 
to the general public, and ensure that it is updated, and managed independently of 
pharmaceutical companies. The subsequent secondary legislation, namely Regulation No 
536/2014 on clinical trials for medicinal products for human use (‘Clinical Trials Regulation’) 
marked a new step in regulation of the EMA ‘transparency’ legislation.  
The ‘Clinical Trials Regulation’ modernized rules on public access to clinical trials data, 
obligating the pharmaceutical company (an applicant) to submit the clinical study report (CSR), 
for all clinical trials, within 30 days after the marketing authorisation was granted16 or within one 
year of the termination of the clinical trial.17 The pharmaceutical companies’ aplications and any 
communication shall be submitted paperlessly via a new electronic EU portal, which is still 
being developed and shall be fully funсtional in late 2019.18 Moreover,  following the 
                                                             
16 Regulation (EU) No. 536/2014 of the European Parliament and of the Council on clinical trials on 
medicinal products for human use, and repealing Directive 2001/20/EC Text with EEA relevance [2014] OJ L 158, 
Art. 37(4)). 
17 Ibid., Art. 37(4). 
18 Ancella Santos Quintano, Till Bruckner, ‘Report: Clinical trials in the European Union - a Roadmap to  
Greater Transparency’ (Health Action International Website, 2019). Available at: http://haiweb.org/wp-
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development and launch of the EU Clinical Trial Portal and Database, all the clinical trial 
information included in the application, such as, for instance the study specific documents (Part I 
of the dossier - the assessment of scientific, therapeutic and safety aspects)19 and the country/site 
specific documents (Part II of the dossier – national reports on the biological samples, clinical 
trial agreements, informed consent, recruitment of subjects etc.)20 – shall already become 
availiable to the public.  
Importantly, the provisions of Art. 81(4) of the Clinical Trials Regulation elaborate 
indirectly on the notion of the ‘commercially confidential information’ which shall be a subject 
to the exclusion from the public access. Similarly to the wording of Regulation (EC) No 
45/2001, the Clinical Trials Regulation elaborates on the  the three stage assessment procedure in 
cases involving the business interests of the enterprises. According to Art. 81(4), the 
abovementioned EU database shall be publicly accessible unless, for all or part of the data and 
information contained therein, confidentiality is justified by the ‘protecting commercially 
confidential information, in particular through taking into account the status of the mark eting 
authorisation for the medicinal product, unless there is an overriding public interest in 
disclosure’.21 However, the distinction could be made between the wordings of these two 
documents: while Regulation No. 1049/2001 protects information which is of ‘commercial 
interest’ for the enterprise, Regulation No 536/2014 directly refers to the term ‘commercially 
confidential information’. The EMA policies (primarily 0043 and 0070) were aimed at defining 
the latter notion, in order to provide the legal framework for the abovementioned three-step 
proportionality test, thus counter-balancing a need to guarantee the business interests of the 
pharma enterprises and the effective public access to the EMA documents. 
b) EMA policies 0043 and 0070. As rightly mentioned by Korkea-Aho and Leino, the 
EMA’s internal guidance differs from that of other EU agencies, in that it seeks to define the 
concept of commercially confidential information extensively by the means of the internal 
implementing legislation, namely the EMA policies and guidances.22 The EMA arguably 
elaborates on this notion in view of the broader public health protection objective, relying on the 
                                                                                                                                                                                                    
content/uploads/2019/02/Clinical-Trials-in-the-EU-A-Roadmap-to-Greater-Transparency.pdf, 5. Accessed 10 
January 2021. 
19 Regulation (EU) No. 536/2014 of the European Parliament and of the Council on clinical trials on 
medicinal products for human use, and repealing Directive 2001/20/EC Text with EEA relevance [2014] OJ L 158, 
Art. 6. 
20 Ibid., Art. 7. 
21 Ibid., Art. 81(4)b. 
22 Emilia Korkea-aho, Päivi Leino, ‘Who owns the information held by EU agencies? Weed killers, 
commercially sensitive information and transparent and participatory governance’ [2017] 54(4) Common Market  
Law Review 1059, 1073-1074. 
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pertienent provisions of European legislation and case-law concerning competition, the 
environment, and public access to documents.23  
For instance, the EMA ‘Principles to be applied for the deletion of commercially 
confidential information for the disclosure of EMEA documents’ (2007) carefully avoided a 
precise definition of this term, proclaiming that the ‘commercially confidential information’ shall 
be generally considered to fall broadly into two categories: (a) confidential intellectual property, 
‘know-how’ and trade secrets (including e.g. formulas, programs, process or information 
contained or embodied in a product, unpublished aspects of trade marks, patents etc.) and (b) 
commercial confidences (e.g. structures and development plans of a company).24 
It has already been mentioned that the shift to the ‘pro-transparency’ approach of the 
EMA policies was defined by the European Ombudsman decision closing her inquiry into 
complaint 2560/2007/BEH against the European Medicines Agency (2010).25 While assesing the 
legality of a request of the Danish researchers to access the EMA clinical study reports and 
corresponding trial protocols for two anti-obesity drugs, the Ombudsman expressed her opinion 
in the sense that the competitors shall generally have a right to access the clinical study reports 
submitted to EMA in course of the authorisation process for the medicine.26 One of the first 
EMA responses was the adoption of Policy 0043 on access to documents implementing the 
provisions of Regulation (EC) No. 1049/2001 and aiming to enhance the transparency of the 
regulatory decision-making process.27  
The main novelties brought by EMA Policy 0043 were the detailed procedure for 
granting public access to the clinical trials data submitted to the EMA in course of the marketing 
authorisation application, allowing for the redaction of the personal data and the commercially 
confidential information – however, without providing any definition of the latter notion.28 The 
EMA Policy 0043 prominently made such an access of an individual or a legal person to the 
abovementioned CT data conditional upon the request, disclosing the identity of the applicant.29 
                                                             
23 Principles to be applied for the deletion of commercially confidential information for the d isclosure o f 
emea documents EMEA/45422/2006 (Official EMA Website, 2007). Available at 
https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/principles-be-applied-deletion-
commercially-confidential-information-disclosure-emea-documents_en.pdf, accessed 10 January 2021. 
24 Ibid., p. 3. 
25 Decision of the European Ombudsman closing his inquiry into complaint 2560/2007/BEH agains t the 
European Medicines Agency (The European Ombudsman Official Website, 2010). Available at 
https://www.ombudsman.europa.eu/en/decision/en/5459, accessed 10 January 2021. 
26 Ibid., paras. 84-94. 
27 European Medicines Agency policy on access to documents (Policy 0043). Available at 
https://www.ema.europa.eu/en/documents/other/policy/0043-european-medicines-agency-policy-access-
documents_en.pdf, 7. Accessed 10 January 2021. 
28 Ibid., 7. 
29 Ibid., 5-6. 
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In the vast majority of cases, EMA granted the requests, but only the applicant was able to 
receive the documents with the agreed redactions.30 
The adoption of the ‘Clinical Trials Regulation’ required further developments of the 
EMA implementing legislation, namely Policy 0070 on publication of clinical data for medicinal 
products for human use.31 The new policy goes a step further by making public the clinical 
trials data proactively - in order to enable public scrutiny and application of new knowledge in 
future research.32 The most prominent features of the Policy are the introduction of a 
publication process on the pertinent EMA website through Terms of Use (Annex 1), as part of 
the Policy: (a) clinical reports are to be available on-screen for any user, with a simple 
registration process (for general information) and (b) downloadable clinical reports available to 
registered identified users (for academic and non-commercial research purposes).33  
The EMA Policy 0070 also defined the ‘commerially confidential information’ as ‘any 
information contained in the clinical reports submitted to the Agency by the applicant/marketing 
authorisation holder (MAH) that is not in the public domain or publicly available and where 
disclosure may undermine the legitimate economic interest of the applicant/MAH’. The general 
approach to the redaction principles is that clinical reports do not contain CCI – even though 
some exceptions still could be made upon the request of the applicant, provided that the 
economic interest at stake is ‘legitimate’. 34 In such cases the EMA shall consider and assess the 
applicant’s justifications for redactions, but still retains the right to make a final decisions on the 
volume of the application kit information which shall be disclosed to public.35  
As the ‘Clinical Trials Regulation’ and the EMA Policy 0070 entry into legal force and a 
publication of the first clinical study reports in October 2016 on the pertinent EMA website 
(https://clinicaldata.ema.europa.eu) predictably met the wave of resistance from the 
pharmaceutical industry.36 The European Medicies Agency promtly responded by releasing the 
‘External guidance on the implementation of the European Medicines Agency policy on the 
                                                             
30 In this sense, see for example Barbara Bierer, Mark Barnes and Rebecca Li, ‘Transparency and Clin ical 
Trial Data Sharing: Legal and Policy Issues’ or Stefano Marino and Spyridon Drosos, ‘The European Medicines 
Agency’s Approach to Transparency’, Chapters 13 and 14 in Holly Fernandez Lynch, Glenn Cohen, Carmel 
Shachar, Barbara Evans (eds.), ‘Transparency in Health and Health Care in the United S tates:  Law and Eth ics’ 
(CUP 2019). 
31 European Medicines Agency policy on publication of clinical data for medicinal products for human use 
(Policy 0070, 2014). Available at https://www.ema.europa.eu/en/documents/other/european-medicines-agency-
policy-publication-clinical-data-medicinal-products-human-use_en.pdf. Accessed 10 January 2021. 
32 Ibid., Section 1. 
33 Ibid., Section 4.2.3. 
34 Ibid., Section 3. 
35 Ibid., Annex 3. 
36 Daria Kim, ‘Transparency Policies of the European Medicines Agency: Has the Paradigm Shifted? ’ 
[2017] 25(3) Oxford Medical Law Review 456, 460-462. 
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publication of clinical data for medicinal products for human use’.37 This document provided 
specific guidelines for companies on the redaction of commercially confidential information and 
data anonymisation to favor proper implementation of Policy 0070. It could be argued that the 
Guidance etsblishes a very high threshold for the companies to be achieved for the discolure of 
the (potentially) commercially confidential information, due to the wague wording of the 
definitions allowing for their broad interpretation.  
For instance, Section 3 lists the following grounds for the refusals for the redaction as the 
information that is already in the public domain or publicly available,38 information that does not 
bear any innovative features,39 additional information the disclosure of which would be in the 
public interest,40 or the information lacking sufficient or relevant justification.41 The 
pharmaceutical enterprises are strongly advised to conduct preliminary research on the subject of 
their MA prior to proposing any redactions - in order to demonstrate the consistency of their 
claims with the level of information already available in the public domain concerning their 
product’s development (e.g. study design and results) and scientific knowledge and 
advancements within the relevant (for the particular product) therapeutic area(s).42 Despite these 
suggestions - it is exclusively within the discretion of the Agency to determine the need in (or 
lack of thereof) to delete the dossier information from the public access, on the basis of the 
investigation of the the grounds for the CCI redaction.43 
 In view of these novelties, the clause of Art. 4(2) of Regulation No 1049/2001 seems to 
be an additonal threat to the pharmaceutical companies: even though the applicant is able to 
demonstrate an economic interest in the redaction which satisfies all strict requirements of 
Policies 0043, 0070 and the External Guidance, even CCI could still be disclosed in case of an 
‘overriding public interest’ (such as the access to the EMA documents and the protection of the 
public health in the European Union). For instance, the EU Court of Justice already mentioned in 
Sweden and Turco that the notion of the ‘overriding public interest’ within this context shall be 
                                                             
37 External guidance on the implementation of the European Medicines Agency policy on the publication of 
clinical data for medicinal products for human use EMA/90915/2016 (External Guidance, 2016). Available at 
https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/external-guidance-implementation-
european-medicines-agency-policy-publication-clinical-data_en-3.pdf. Accessed 10 January 2021. 
38 Ibid., Section 3.2.1. 
39 Ibid., Section 3.2.2. 
40 Ibid., Section 3.2.3. 
41 Ibid., Section 3.2.4. 
42 Ibid., Section 3. 
43 Ibid., Section 3.3.1. 
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interpreted in light of the principles underlying Regulation No. 1049/2001,44 such as an effective 
realisation of the right to public access to the EU documents.45  
Considering the ‘pro-transparency’ approach to the disclosure of the EMA documents 
which was clearly articulated by the European Ombudsman since 2010, the guidance on such a 
balancing test from the CJEU, also in view of the ‘overriding public interest’ concept was 
clearly needed. One of the sensitive issues has also been the CJEU’s approach to the EU Charter 
of Fundamental Rights (CFREU) provisions, as the applicants started to put forward the 
CFREU-based claims, in order to protect the (potentially) commercially confidential information 
from the disclosure on the basis of the EMA Policies 0043 and 0070.  
 
2. The EMA transparency policies: the CJEU triggering the CFREU provisions 
As said by Maulenbelt, since the CJEU generally abstrains from the substanive analysis 
of the ‘science-related’ decisions of the EU Agencies, the review of the EMA decisions could be 
seen as ‘marginal’ and thus not providing the adequate legal protection to the pharma 
companies.46 In view of the Ombudsman ‘pro-transparency’ statements, it could be argued that 
the Charter of Fundamental Rights of the EU has become a legal basis for the pharma industry 
attempts to defend the most precious component of the MA applications, namely the scientific 
research results from the disclosure to the wide public. The research conducted on the CURIA 
website demonstrated that in total the CFREU provisions was already invoked in 10 judicial acts 
(including Orders) concerning the EMA approach to the disclosure of the documents submitted 
as a part of the MA applications by the pharmaceutical undertakings.    
Since the Policy 0043 entry into force, several pharmaceutical companies have objected 
to the EMA’s decision to disclose their clinical reports – which resulted in the interim measures 
suspending the EMA’s decisions in order to prevent serious and irreparable harm to the 
applicant’s business interests.47 The first application was AbbVie v. EMA concerning the scope of 
the EMA competence to disclose details of clinical trials involving AbbVie’s rheumatoid 
arthritis drug Humira, one of the world’s top-selling prescription medicines.48 In this case, a 
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university science student claimed for access to three clinical study reports submitted by AbbVie 
in connection with the preparation of his Master’s thesis.49  
The AbbVie reiterated its refusal to consent to disclosure of the documents, stating that 
the three clinical study reports were covered by the exception of Art. 4(2) of Regulation No 
1049/2001 (‘commercially confidential information’) and reiterating the concerns expressed in 
relation to the previous request for access to similar documents concerning Humira. However, 
the EMA decided to grant the request for access filed by the student on the basis of Policy 0043 
(2010), mentioning that clinical study reports on medicinal products could not be regarded as 
confidential information.50 The company predictably objected the disclosure and submitted the 
request for the interim measures from the General Court. 
Firstly, the AbbVie argued that that disclosure of the disputed reports before the end of 
the main proceedings would deprive them of the right to an effective remedy, enshrined in Art. 
47 of the EU Charter (corresponding to Art. 6 of the European Convention on Human Rights).51 
Secondly, the disclosure under Regulation No. 1049/2001 has erga omnes effect and thus clearly 
presents a danger for the business interests of the enterprises, preventing the relevant institution 
from objecting to dissemination of that document to other parties requesting access and allowing 
anyone to have access to it (i.e. the science student can arguably provide the document to the 
competitors).52 Thirdly, the EMA decision was solely based on new Policy 0043 since 2010 - 
noted that the lawfulness of that policy has not (at that point of time) been ruled on by the 
European Union courts. Hence, these factors could potentially infringe the applicants’ right to 
respect for its private life (and business secrecy), as guaranteed by Art. 339 TFEU and Art. 7 of 
the EU Charter (corresponding to Art. 8 ECHR), as the disputed reports shall arguably be 
considered confidential in nature. A question of such crucial importance cannot be ruled on for 
the first time by a judge hearing an application for interim measures.53 
In view of this reasoning, the General Court held that the AbbVie’s request for interim 
measures satisfied the requirement of urgency and was justified in fact and law, since the 
disclosure of the clinical study reports may irreparably infringe AbbVie’s right to protection of 
its business secrets and its right to a private life – referring both to Arts. 7 and 47 CFREU, as 
well as Art. 8 ECHR as a part of the legal reasoning. These fundamental rights were likely to be 
jeopardised if the EMA was allowed to disclose the CSRs before the General Court final 
judgement in the case. The interim measures was accompanied by the careful statement:’The 
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legal situation created by interim proceedings must be reversible, it must be recalled that the 
purpose of the procedure for interim relief is merely to guarantee the full effectiveness of the 
future decision on the main action’.54 Importantly, the abovementioned Order became a subject 
to the appeal to the EU Court of Justice – however, the precise scope of the CCI protection in 
view of Policy 0043 and the CFREU provisions (Arts. 7 and 47) remained without further 
elaboration at that point of time. The EMA and the pharmaceutical company AbbVie had 
concluded an agreement, according to which the EMA could grant public access to the redacted 
versions of AbbVie’s clinical reports.55 
The ‘twin’ case of EMA v InterMune UK and Others concerned the access requested by 
the pharmaceutical company Boehringer Ingelheim GmbH to the clinical reports submitted for 
the MAA of InterMune’s drug Esbriet for idiopathic pulmonary fibrosis treatment.56 Under 
interim decision adopted under similar circumstances, the EMA was ordered by the General 
Court not to provide the requested documents until a final ruling was given, with a similar legal 
reasoning based on Arts. 7 and 47 of the EU Charter.57 In InterMune UK, the CJEU prominently 
set aside the Order and referred the case back to the General Court for assessing the possibility of 
a partial disclosure of information (i.e. with the necessary redactions).  
The CJEU’s overall approach to the InterMune UK case analysis allows to argue that, in 
view of the Court, just claiming a violation of the EU’s fundamental rights (primarily Art. 7 
CFREU) in itself was generally not sufficient to substantiate the threat of a serious and 
irreparable damage, while the commercial value of the information seemed to be a decisive 
factor.58 An important clarification of the CCI notion was also made: the professional and 
commercial importance (value) of such information for the undertaking depends – among other 
factors – on the utility of that information for other undertakings which are able to examine and 
use it subsequently.59 However, just like in AbbVie, the case was eventually settled outside of 
court since the EMA and InterMune UK agreed on the volume of necessary redactions in the 
requested documents before the disclosure.60  
The InterMune UK case were seen by some scholars as the missed opportunity to provide 
an interpretation of the ‘commercially confidential information’ within the meaning of the EMA 
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Policy 0043, and thus a comprhensive guidance for the (non-) dislosure of such information.61 
The simulataneous intervention of the European Ombudsman could serve as an additional 
argument in this regard. While the InterMune UK was heard by the CJEU, Mrs. Emily O’Reilly 
criticised the AbbVie Orders and  encouraged the European Medicines Agency  ’in the case of 
the clinical study reports at issue in the present inquiry, to reconsider the need to retain the 
remaining redactions, made for the purpose of protecting commercial interests, if it receives new 
requests for access to these reports’.62 The main rationale of the Ombudsman was a need ‘to 
ensure continuing systemic improvements’ of the EMA activities, in view of the ‘overriding 
public interest for documents to be disclosed where the information they hold has clinical value 
to clinicians and researchers’.63 
   Hence, the AbbVie/ InterMune UK outcomes did not provide a clear legal definition of 
commercial confidentiality – either in view of Art. 7 and 47 CFREU and/or Policy 0043 
provisions, opening the floor for future cases. Three subsequent court cases with the very similar 
factual background also concerned the EMA’s decision to release the documents in accordance 
with the ‘Transparency Regulation’. The claims were brought to EMA by Pari Pharma 
(disclosure of similarity and superiority reports on an orphan medicine, prepared by the EMA 
Committee for Medicinal Products for Human use),64 PTC Therapeutics International (disclosure 
of a clinical study report)65 and MSD Animal Health Innovation/Intervet international (five 
toxicology study reports for a veterinary medicine).66  
In these proceedings each party sought recourse from the Court to prevent the publication 
of clinical and nonclinical study reports, arguing that these must be regarded as trade secrets and 
as such, must not be disclosed. The claimants’ position was that the entirety of the information in 
the clinical trial reports, especially the compilation of publicly accessible clinical data and the 
analysis of this data by various third parties, as well as the general authorisation deliberations , 
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must be generally regarded as confidential.67 Pari Pharma, PTC Therapeutics International, MSD 
Animal Health Innovation put forward the AbbVie/InterMune inspired argumentation, relying on 
the CFREU provisions as a legal basis for the claims.  
For instance, the Pari Pharma representatives elaborated on the substance of fundamental 
rights as regards private life and confidentiality under Art. 7 of the EU Charter and Art. 8 of the 
European Convention. The applicant maintained that disclosure of the reports at issue would 
undermine its business secrets, the Court of Justice having recognised that it may be necessary to 
prohibit the disclosure of information which is classified as confidential, and the protection 
provided by those provisions of primary law cannot be undermined by a mere administrative 
practice, such as the EMA’s Policy 0043.68 Interestingly, the intervener in the PariPharma case 
which requested the EMA to disclose the reports at issue argued that Art. 47 CFREU (right to an 
effective remedy even in the administrative proceedings) shall be interpreted as a ground for 
providing access to the reports at issue. The main argument behind that was the competing 
business interest, namely the protection of the market exclusivity of its medicinal product TOBI 
Podhaler and supporting its action for annulment of the decision by which the Commission 
granted the applicant the MA for Vantobra (PariPharma drug).69  
 In PTC Therapeutics International, the claimants mentioned that Art. 42 CFREU 
guaranteeing the access to the EU documents is a subject to the legitimate limitations, such as the 
business secrets of the legal persons.70 Thus, the contested EMA decision shall be seen as 
infringing, inter alia, the first indent of Art. 4(2) of Regulation No 1049/2001, Art. 339 TFEU 
and the fundamental rights of the enterprise as regards the protection of privacy and of 
professional data under Art. 7 of the EU Charter and the Varec case.71 In the MSD Animal Health 
Innovation GmbH case, the applicants put forward very similar reasoning, claiming that the 
contested decision infringes, inter alia, Art. 4(2)a of Regulation No 1049/2001, Art. 339 TFEU 
and their fundamental rights regarding respect for private life and correspondence under Art. 7 
CFREU – as there is no emerging ‘overriding public interest’ justifying their disclosure.72 The 
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claimants’ suggestion was adding a new step in the EMA assesment on the basis of 
‘Transparency Regulation’ and Policy 0043, in order to counter-balance the compteting CFREU 
rights (i.e. Art. 42 vs. Art. 7) - for instance ‘limited disclosure to independent academic 
researchers who would not use the information for commercial purposes’.73 
In view of this reasoning, the claimants asserted not only that the especially sensitive 
parts of the reports should be covered by confidentiality protection, but rather, that this 
protection must extend to the reports as such, because the sensitive parts are embedded in a 
series of arguments, which includes questions relating to their respective strategy and together 
with other public elements of the reports, constitute an inseparable entity with economic value.74 
However, the Court dismissed a general presumption of confidentiality for such documents in all 
three cases. As for the fundamental rights’ arguments of the applicants, the CJEU prominenetly 
disregarded the Charter-based claims: the PTC Therapeutics International Ltd and MSD Animal 
Health Innovation GmbH final judgements do not contain any mention of the Arts. 7 CFREU 
provisons. In the Pari Pharma GmbH case, the Court extensively elaborated on the company 
pleas, which were complimented by the references to the provisions of Art. 16 (‘Freedom to 
conduct a business’) and 17 (‘Right to property’) of the EU Charter.75 
The CJEU heavily criticised the parties’ assumption that the entire contents of the CT 
reports are confidential, as a significant part of the information contained in those reports is in 
the public domain and cannot by definition be regarded as falling within the scope of commercial 
interest within the meaning of Art. 4(2) of Regulation No 1049/2001. The applicant cannot 
therefore rely on the possible infringement using Art. 339 TFEU, Arts. 7, 16 and 17 CFREU and 
Art. 8 ECHR as a relevant legal ground for such a claim since it does not appear that all the data 
to which it refers are confidential. The importance of the pharma enterprise conduct in 
bargaining the pertinent redactions was emphasised: ‘...it is thus for the applicant to identify and 
show which information, in its submission, falls within the scope of commercial interests within 
the meaning of 4(2) of Regulation No. 1049/2001’.76 
Hence, the court concluded in all three cases that, pursuant to Art. 2(3) of Regulation No. 
1049/2001 that the provisions regarding the public accessibility of EMA documents shall apply 
to all documents of the agency, in all of its areas of activity, i.e. to all documents the agency 
creates or receives and which are in its possession. In light of the need for strict interpretation of 
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Art. 4(2) exceptions (confidential business information), the CJEU said that the EU’s legislator 
presumed that the integrity of the authorisation process is not impaired by the absence of such a 
presumption of confidentiality. For all these reasons, the General Court concluded that shall be 
no general presumption of confidentiality for CT reports; it is not possible to presume that these 
reports are subject to general confidentiality that would cover them in their entirety based on the 
exception to protect the economic interests of the applicant. Even though the economic value of 
the dossier is important for the pusposes of the Policy 0043 application, it is not sufficient on its 
own to classify as a ‘commercially confidential information’ and therefore as confidential. 
Rather, it is up to the EMA to ensure, by conducting a specific, individual examination of each 
individual document in the administrative file to determine whether the document is covered as 
an exception for trade secrets within the meaning of Art. 2(4)a Regulation No. 1049/2001. 
An initial CJEU’s rulings in PTC Therapeutics International and MSD Animal Health 
Innovation/Intervet international were thus in favour of EMA. They went to appeal and, in 
September 2019, an AG Hogan released Opinions with a very ‘pharma enterprises friendly’ 
argumentation.77 However, the CFREU-based reasoning did not even appear in the texts - except 
for a very brief mention in the introductory parts paving way to the legal analysis. Advocate 
General preferred to put forward another arguments to defend the incorporation of the 
presumption of general confidentiality as the lack of effective safeguard clauses stemming from 
EU secondary legislation, which - moreover – is applicable only within the territory of the 
European Union/European Economic Area (EEA). This circumstances presumably open the 
floor for the usage of the costly ´R&D  ́ commercial data in non-EEA countries. Crucially, such 
presumption would give companies at least a right to an injunction, forcing the CJEU to consider 
the merits of a particular case and assess an objective need in a disclosure, instead of simply 
disregarding the CCI protection claims automatically.78 
The appeal judgements in two of these cases however demonstrated the lack of the 
CJEU ś intention (1) to consider even a possibility to implement the presumption of general 
confidentiality of the clinical trial reports submitted as a part of the EMA authorisation kit or (2) 
to consider the CFREU provisions as a tool to defend the commercial interests of the 
pharmaceutical enterprises. Both in PTC Therapeutics International and MSD Animal Health 
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Innovation/Intervet international appeal judgements, the Court did not follow the AG 
suggestions. The Luxembourg judges pointed out that the claimants have not provide sufficient 
evidence, in order to demonstrate that the disclosure of the CCI in question could be considered 
potentially harmful to their business interests. From the judges’ point of view, the mere risk  that 
a competitor uses the data for economic purposes cannot be considered a sufficient ground for 
application of general presumption of the confidentiality.79 
Even though the rulings – predictably – continue the ‘pro-transparency’ trend, an 
important technical clarification was made on how to deal with information which shall – from 
the point of view of the pharma enterprise – be defended from the disclosure, in absence of the 
presumption of confidentiality. Pharmaceutical companies that want to prevent third parties from 
viewing the documents from the EMA authorisation kit are now requested to justify explicitly a 
need in an individual application of the exemptions laid down in Art. 4 of Regulation No 
1049/2001. Based on this reasoning, the EMA can then individually assess whether or not to 
provide the requested information in accordance with the detailed description of the (a) type, (b) 
subject matter, (c) scope of this data, as well as (d) the explanation of how the dissemination of 
CCI can realistically affect the business interests of the enterprise.80 
The recent CJEU’s judgement in Intercept Pharma Ltd/Intercept Pharmaceuticals 
confirmed the well-established practice, and demonstrated the final demise of the CFREU 
provisions in cases involving the EMA ‘transparency’ policies. The claim concerned an EMA 
decision to grant an access pursuant to Regulation No. 1049/2001 to a document containing 
periodic benefit-risk evaluation report submitted to the EMA as part of the application for 
marketing authorisation of a medicinal product for human use called Ocaliva. The specificity of 
the dispute was defined by the fact that the requesting party was a counterpart of Intercept 
Pharma Ltd in the legal dispute being considered in the United States of America, as such access 
would not be possible in accordance with American laws.81  
In view of the specific legal context of the dispute and – presumably – the ealier Court 
judgements completely ignoring the EU Charter-based arguments of the pharamceutical industry, 
the claimant referred to Art. 4(2)2 of Regulation No. 1049/2001 according to which a request for 
access to documents can be denied if disclosure would be undermining the protection of court 
proceedings and legal advice (i.e. of the dispute ongoing in the USA court), unless there is an 
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overriding public interest in disclosure. The CJEU found that the contested report has neither 
been drafted for a judicial process in question, nor had it been the subject of such a procedure. 
Hence, making the application of the exception relating to ongoing trial(-s) between the 
applicant and the (legal) person requesting an access to the EMA marketing authorisation kit as 
such would unacceptably broaden the scope of the Art. 4 of Regulation No. 1049/2001 
exception. The Court therefore decided to reject the appeal in full and to confirm the sentence of 
General Court and the earlier EMA decision,82 hence – again – deliberately confirming its well 
established ‘pro-transparency’ case-law. 
Finally, the ‘Clinical Trials Regulation’ implementation can arguably bring even more 
challenges to the EMA/pharma enterprises relationship, in view of the final move towards the 
proactive publication of the CT data. One could also remember that – upon the planned launch of 
the ‘Clinical Trial Data Portal/Database’ in late 202183 – the implementing provisions of EMA 
Policy 0070 are also likely to become a fruitful basis for the litigation before the EU Court of 
Justice. The first evidence of this development is the Amicus Therapeutics UK and Amicus 
Therapeutics v EMA case, regarding public access to a document containing information 
submitted in the context of a request for marketing authorisation for the medicinal product 
Galafold.84 Even though the case concerned the implementation of Policy 0043, the EMA also 
referred to the text of new Regulation (EU) No. 536/2014 (‘Clinical Trials Regulation’) and, in 
particular, to Arts. 37(4), 80 and 81 and recitals 67 and 68 thereof, in order to support its 
submissions.85 
The CJEU prominently disregarded the applicants’ fundamental rights’ claims, referring 
to the Deza v ECHA case outcome. Both Art. 8 ECHR, Art. 7 and Art. 17 of the EU Charter 
cannot be interpreted as laying down an automatic exception to the principle of disclosure for 
documents drawn up in the course of a private entity’s commercial activity. Even though new 
Regulation No. 536/2014 on clinical trials on medicinal products for human use was considered 
inapplicable in the present case, the Court saw the wording of the abovementioned provisions as 
an additional indication that EU legislature was specifically aiming at the maximum 
transparency of the EMA documents.86 Hence, it was emphasised that the objectives of 
(applicable) Regulation No. 1049/2001 and EMA Policy 0043 exclude the existence of a general 
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presumption of confidentiality87 – which means that EMA must specifically examine the various 
data concerned by the request for access.88 In order to justify a refusal to grant access to a 
document, it is not even sufficient for that document to fall within an activity mentioned in Art. 4 
of Regulation No 1049/2007 – on the ground that there is an overriding public interest in 
disclosure, namely a need to ensure that the a marketing authorisation procedure operates 
correctly, and a disclosure of the report at issue cannot alter that procedure.89 
In sum, the EU Court of Justice tended to analyse the objectives of the Transparency 
Regulation, Authorisation Regulation, and the pertinent provisions of Policy 0043, interpreting 
Art. 7 of the EU Charter or - later - simply avoiding the CFREU-based arguments to favor the 
ever increasing transparency through both reactive and proactive publication of the MA files 
components. It could be stated that the CJEU’s approach to the interpretation of the 
abovementioned Charter provisions in years to come, is unlikely to be changed. This creates, 
inter alia, the growing risk of the (possible) violation of the rights of the pharmaceutical 
companies (for instance, Arts. 16, 17 and 47 CFREU), as well as the deriving need in 
intensification of the dialogue between the pharma enterprises and the European Medicines 
Agency (‘redaction’ process). However, the CJEU also indicated how the fundamental rights of 
pharmaceutical companies shall be protected in course of the latter procedure – and which level 
of the business guarantees the CJEU and EMA see as sufficient within this context. The 
‘commercially confidential information’ still can be redacted (even though not excluded from the 
public access in its entirety), if the enterprise concerned is able to demonstrate how access to that 
document could specifically and actually undermine the interest protected by an exception laid 
down in Art. 4 of Regulation No 1049/2001 and that the risk of that interest being undermined is 
reasonably foreseeable and not purely hypothetical.90 
 
3. The EMA ´transparency´ policies & COVID-19: is the CFREU still relevant? 
As of October 2020, more than 4 million COVID-19 cases have been reported in the 
EU/EEA and the United Kingdom; nearly all countries belonging to this area were 
experiencing high levels or sustained increases of their 14-day COVID-19 case notification 
rate.91 Predictably, the enexpected COVID-19 pandemia caused an unprecedented public interest 
in medicine being developed specifically for this desease, as well as the need to provide access to 
                                                             
87 Ibid., paras. 50-51. 
88 Ibid., para. 59-61. 
89 Ibid., para. 41. 
90 Case T-33/17, Amicus Therapeutics UK Ltd and Amicus Therapeutics, Inc v European Medicines Agency 
(EMA) [2018] ECLI:EU:T:2018:595, para. 59. 
91 Communication from the Commission to the European Parliament and the Council, COM(2020) 680 
final, p. 2. 
21 
 
more information than usual in course of the European Medicines Agency authorisation 
procedures.92 The pan-European race to produce COVID-19 treatments, ranging from 
immunomodulators, antivirals and hyperimmune serums was also seen as a possibility for 
regulators and drug companies to lobby for a more harmonised approvals process,93 considering 
both the prevailing public interest in coping a disease and respecting the commercial interests of 
the pharmaceutical enterprises.94  
Within the framework of Decision 1082/2013/EU on serious cross-border threats to health, 
and in view of the emerging health threat to humans in the European Union territory, the COVID-
19 EMA Pandemic Task Force (COVID-ETF) was established.95 One of the key objectives of 
this emergency Group was articulated as managing and coordinating the discussions ‘…on 
development, authorisation and surveillance of relevant medicinal products, which are under the 
remit of EMA, and post-authorisation follow-up of all relevant EU authorised medicinal products 
to be used to address the health threat’.96 Importantly, the basic EMA transparency documents, 
namely EMA Policies 0043 and 0070 were not urgently revised either due to these developments, 
or due to the CFREU-based applicants’ arguments of the AbbVie/InterMune lines of reasoning.97 
The inquiry of the scientists from IQWiG and the Cochrane Collaboration to the 
European Medicines Agency (EMA)98 was one of the first public responses to these novelties. 
The academics called for the accelerated publication of all clinical study reports on all COVID-
19 drugs and vaccines as soon as they are approved for the EU/EEA market – in order to pool the 
strengths of international research community to combat the pandemic.99 Their request was 
followed by the open letter of the European Ombudsman: on 29 July, 2020, Mrs. O’Reilly 
                                                             
92 Milad Haghani, Michiel Bliemer, ‘Covid-19 pandemic and the unprecedented mobilisation of s cholarly  
efforts prompted by a health crisis: Scientometric comparisons across SARS, MERS and 2019-nCoV literature’ 
(2020) 125 Scientometrics 2695. Avaliable at: https://doi.org/10.1007/s11192-020-03706-z, accessed 10 January 
2021. 
93 Editorial: ‘COVID vaccines: the world’s medical regulators need access to open data’ (2020) 588(7837) 
Nature 195. Avaliable at: https://www.nature.com/articles/d41586-020-03458-z, accessed 10 January 2021. 
94 Adam Cohen, Joop van Gerven, Juan Garcia Burgos, ‘COVID‐19 vaccines: the importance of 
transparency and fact‐based education’ (2020) 86(11) British Journal of Clinical Pharmacology 1. Avaliable at: 
https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14581, accessed 10 January 2021. 
95 EMA/166423/2020 (31 March 2020), ‘Biological Health Threats and Vaccines Strategy Mandate, 
objectives and rules of procedure of the COVID-19 EMA pandemic Task Force (COVID-ETF)’. Avaliable at: 
https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-covid-19-ema-pandemic-task-
force-covid-etf_en.pdf, accessed 10 January 2021. 
96 Ibid., p. 1.  
97 Policy 0043 is expected to be reviewed before 31 October, 2021 – considering the outcomes of the 
COVID-19 outbreak, BREXIT implications and deriving developments in the EMA implementing documentation.  
Response to ASK-74893 - EMA transparency policies in light of COVID 19, received on 10 December 2020, p. 3-4. 
98 EMA should support the international research community by publishing Clin ical Study  Reports on  
medicine and vaccine trials at the time of marketing authoris ation’ (IQWiG, 14 May 2020). Available at:  
https://www.iqwig.de/printprodukte/2020-05-14open20letter20to20emafinal.pdf?rev=117386, accessed 10 January, 
2021. 
99 Ibid., p. 1, 2. 
22 
 
requested the information on the EMA’s intention (1) to follow earlier ‘pro-transparency’ 
decisions of the European Ombudsman in the activities of the COVID-ETF Group, and (2) to 
ensure sufficient degree of transparency of its COVID-19 related activities, including the 
possibility of rapidly publishing clinical data for the products in question.100 Surprisingly, the EU 
Charter provisions were not mentioned either by the European Ombudsman, or by the EMA 
Executive Director. In his replies, Dr. Rasi simply wrote that EMA’s activities in relation to 
COVID-19 deserve the highest possible level of transparency and, in keeping with our 
commitment, the Agency will take appropriate action to share information publicly.101 This 
position was predictably retained in the EMA response to the second open letter from the 
members of academic community concerning the transparency and evaluation of vaccines for 
COVID-19.102 
Moreover, it was underlined that, despite all challenges related to the COVID-19 
outbreak, the maximum efforts should be put into implementing exceptional transparency 
measures with regard to the relevant medicines being assessed under accelerated procedures such 
as rolling review.103 For instance, such exceptional measures for COVID-19 medicines 
assesment comprise the (online) publishing of the list of the relevant medicines that have 
received scientific advice by the European Medicines Agency on the appropriate tests and 
studies required in the development of a medicine or on the quality of a medicine or guidance 
from the EMS COVID-ETF Group, announcement of the news on compassionate use of the 
unauthorised drugs outside a clinical study in individual patients within 1 day of the Committee 
for Medicinal Products for Human Use (CHMP) opinion, on the start of rolling review of such 
medicines within 1 day after the review start, as well as on the submission of the marketing 
authorisation application within 1 day after such application was made.104  
                                                             
100 Let ter to  the European  Medicines  A gency  (EMA ) concern ing  the t rans parency  and  
independence of the work of the EMA in supporting the development  a nd e valuat ion  o f CO VI D - 19  
medicines  (CA SE SI/5/2020/DDJ, 29 Ju ly , 2020). Available at: 
h t tps:/ /www.ombudsman.europa.eu/en/correspondence/en/130852, accessed 10 January, 2021. 
101 EMA/516771/2020 (30 September 2020), ‘Reply to the European Ombudsman’s letter concerning 
transparency and independence of the work of the European Medicines Agency in supporting the development and 
evaluation of COVID-19 medicines’.  Available at: https://www.ema.europa.eu/en/documents/other/reply-european-
ombudsmans-letter-concerning-transparency-independence-work-european-medicines-agency_en.pdf, accessed 10 
January, 2021. 
102 EMA/565800/2020 (29 October, 2020) Reply to open letter concerning the transparency and evaluation 
of vaccines for COVID-19. Available at: https://www.ema.europa.eu/en/documents/other/reply-open-letter-
concerning-transparency-evaluation-vaccines-covid-19_en.pdf, accessed 10 January, 2021. 
103 Ibid., p. 1. 
104 ‘Transparency: exceptional measures for COVID-19 medicines’.  Available at: 
https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-
19/treatments-vaccines/transparency-exceptional-measures-covid-19-medicines#comparison-with-standard-
transparency-section, accessed 10 January, 2021. 
23 
 
The major changes concerned the authorisation process as such. For example, the 
publication of the EMA COVID-related European public assessment report (EPAR, i.e. a set of 
documents describing the evaluation of a medicine and including the product information) shall 
be made within 3 days of granting marketing authorisation , with the updates following major 
post-authorisation changes – while normally being published at least 2 weeks after marketing 
authorisation granting. In case of the COVID medicines, the risk management plans (RMP, i.e. a 
detailed description of the activities and interventions designed to identify, characterise, prevent 
or minimise risks relating to medicines) shall be released fully (not as a summary), with the 
updates following major post-authorisation changes.105  
The COVID-19 clinical trials data shall be published on Clinical data 
website106 after granting marketing authorisation, with an additional data also released after 
major changes to authorisation.107 Hence, even though the COVID-19 pandemic did not have an 
impact on the overall development of the CT Portal, with the publication of clinical trials data 
remaining suspened for all other medicinal products until further notice,108 the abovementioned 
documents related to COVID medicines development became availiable both to the EU public, 
as well as the non-EU individuals and enterprises. Pharmaceutical companies were encouraged 
to contact EMA as soon as possible concerning publication of clinical data if they planned to 
submit an application for the COVID-19 related medicinal products.109 
In line with this ‘pro-transparency’ strategy, the European Medicines Agency has already 
published an information on more than 70 COVID-19 medicines that had received EMA advice. 
Among them, 8 vaccines, 18 immunomodulators, 1 immunoglobulin, 1 challenge agent for 
human infection models, 24 antiviral drugs and 4 other therapeutics.110 Importantly, the 
EMA’s conditional marketing authorisation (CMA) mechanism was used for the COVID-19 
medicines as they potentially addressed an unmet medical need, with the benefit of immediate 
availability outweighing the risk – on the basis of less comprehensive data than normally 
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required.111 The application for the marketing authorisation of Remdesivir - a treatment against 
COVID-19 for adults and adolescents as from age 12 with pneumonia who require supplemental 
oxygen - was submitted to the European Medicines Agency on 8 June, 2020.112  
In course of the latter procedure, an information on the key COVID sympthomatic 
treatment Remdesivir, including 18 clinical trials protocols,113 product information, EPAR and 
and EMA Committee for Medicinal Products for Human Use (CHMP) Opinion were published 
online.114 An applicant (Gilead Sciences Ireland CU) did not attempt to invoke the EU Charter 
provisions (Arts. 7, 16, 17, 47 and 42 for instance) as a ground to block access of the third 
persons to the application kit submitted to the EMA (as a ‘commercially confidential 
information’ exception), or as a ground for the redaction of the CMA application kit. 115 On 3 
July, 2020 - after the EMA’s recommendation and subsequent approval of the Standing 
Committee on Medicinal Products for Human Use - Remdesivir became the first treatment to be 
authorised for a conditional marketing under abovementioned accelerated procedure.116 This 
EMA decision allowed to implement it widely as a COVID-19 symptomatic treatment in clinical 
practice across the European Union.117  
The second essential COVID-19 treatment, namely Dexamethasone for the usage in adult 
and adolescent patients (aged 12 years and older with body weight at least 40 kg) who require 
supplemental oxygen therapy – was authorised for the European Union in accordance with the 
Art. 5(3) of Regulation (EC) No 726/2004 (‘Submission and examination of applications — 
Authorisations’). Dexamethasone is a corticosteroid medicine that has been authorised in the EU 
by national medicines authorities and has been available for several decades for treating a range 
of inflammatory conditions and for reducing the body’s immune response in the treatment of 
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allergies and autoimmune diseases.118 At the same time, the ‘Randomised Evaluation of COVID-
19 therapy’ (‘RECOVERY’) clinical trials conducted in the United Kingdom119 indicated a 
potential benefit of dexamethasone in adult hospitalised patients with COVID-19 receiving 
invasive mechanical ventilation or oxygen supplementation and in hospitalised patients with 
more than 7 days after symptom onset.120 
On 17 July 2020, the EMA Executive Director - following preliminary discussion with 
the COVID-ETF Group - asked the CHMP to assess the impact and give a scientific opinion on 
potential clinical use of Dexamethasone in the treatment of hospitalised adult patients with 
COVID-19, for oral and intravenous medicinal products.121 In accordance with Art. 5(3) of 
Regulation (EC) No. 726/2004, the opinion of the Committee shall be made publicly 
accessible.122 Assessment report as adopted by the CHMP with all information of a 
commercially confidential nature deleted.123 However, the CFREU provisions (Arts. 7, 16, 17, 47 
or 42) were not referred to as a ground to block access of the third persons to the application  kit 
(as a ‘commercially confidential information’ exception), or as a ground for the redaction of the 
RECOVERY clinical trials reports submitted to the EMA.124 On the basis of CHMP positive 
Opinion from 17 September 2020, the EMA endorsed use of dexamethasone in COVID-19 
patients on oxygen or mechanical ventilation, and the pharmaceutical companies 
producing/distributing Dexamethasone were encouraged to request this new use to be added to 
their product’s license by submitting an application to national medicines agencies or to 
European Medicines Agency.125 
Predictably, the COVID-19 vaccine development was supported by the transparent and 
continuous dialogue between the pharameceutical companies and the EMA COVID-ETF 
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Group,126 which led to the European Commission preliminary supply contracts with several 
pharmaceutical companies, comprising BioNTech-Pfizer, Moderna, AstraZeneca, Sanofi-GSK 
and Janssen Pharmaceutica NV and CureVac.127 This approach was aimed at the creation of the 
broad portfolio of vaccines to be provided in the EU Member States, once all the vaccines in 
question have been proven to be safe and effective and authorised by EMA.128 At the time of 
writing, two effective vaccines against COVID-19 – namely Comirnaty (BioNTech and Pfizer) 
and Moderna (Moderna) - have also been granted a conditional authorisation for use in the 
European Union, following positive assessment of the preliminary research results by the 
European Medicines Agency.129 The clinical studies are not yet complete, and the 
pharmaceutical companies are expected to provide the final results of their COVID research in 
the forthcoming years. This means that the final clinical trials reports are still in the progress of 
development, and shall be released upon full completion and assessment of Moderna and 
Comirnaty clinical trials.130 
The first authorised vaccine is Comirnaty developed by BioNTech and Pfizer, aimed at 
preventing coronavirus disease in people aged 16 years. The effective substance contains a 
molecule called RNA messenger with guidance for producing a protein from SARS-CoV-2, the 
virus that causes COVID-19.131 The applicant (BioNTech Manufacturing GmbH) submitted an 
application for marketing authorisation on 30 November 2020, through the centralised 
authorisation procedure under Regulation (EC) No. 726/2004.132 The effectiveness of the vaccine 
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was demonstrated by the results on the clinical trials conducted in the United States, Turkey, 
Germany, South Africa, Brazil, Argentina, and confirmed by the national inspection resports, 
such as ones prepared by the Regierungspräsidium Karlsruhe and Paul-Ehrlich-Institut 
(Germany), Food and Drug Administrations (USA Regulatory Authority) and National 
Administration of Drugs, Foods and Medical Devices (Argentinian Regulatory Authority) 
enclosed with the EMA application.133 
The Comirnaty EPAR was adopted by the Committee for Medicinal Products for Human 
Use and released online with all information of a commercially confidential nature deleted.134 
The CFREU provisions (Arts. 7, 16, 17, 47 or 42) were not referred to as a ground to block 
access of the third persons to the application kit (as a ‘commercially confidential information ’ 
exception), or as a ground for the redaction of the BNT162b2 application file  submitted to  the 
European Medicines Agency.135 On 21 December 2020, following the CHMP ś preliminary 
positive assessment of quality, safety and efficacy of the vaccine, Comirnaty was granted a 
conditional marketing authorisation for the distribution in the European Union.136The European 
Commission already approved the contracts with BioNTech-Pfizer for the purchase of 400 
million doses on behalf of all EU Member States (total), and proposed to the EU Member States 
the purchase of an additional 300 million Comirnaty vaccine doses (total).137 
The second COVID vaccine authorised in the European Union is Moderna developed by 
Moderna Biotech Spain, which can be used to prevent  disease in people from 18 years of age. 
The effective substance – just like in Comirnaty - contains similar RNA molecule-messenger 
with instructions for producing a protein from the virus that causes the Coronavirus.138 The 
second vaccine was also assesed under accelearted procedure, with the start of the CHMP ’s 
rolling review even before the pharmaceuttical company’s application for the product 
authorisation - in order to speed up the assessment of a medicine addressing a public health 
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emergency.139 The safety of the vaccine was assessed on the basis of results of the clinical trials 
conducted in the United States involving 30,351 participants 18 years of age and older.140 
The CHMP summary of positive opinion for COVID-19 Vaccine Moderna, Product 
information and the Risk-management-plan were published on the EMA website on 6 January, 
2021,141 with the EPAR being prepared for the publication at the time of writing.142 The CFREU 
provisions (Arts. 7, 16, 17, 47 or 42) were not referred to as a ground to block access of the third 
persons to the application kit (as a ‘commercially confidential information’ exception), or as a 
ground for the redaction of the Moderna application file submitted to the European Medicines 
Agency.143 Following a positive EMA assessment, Moderna was granted a conditional marketing 
authorisation for the distrubuton and usage in the European Union on 6 January, 2021.144 The 
European Commission approved the suppy contracts with Moderna for the purchase of 80 
million doses of COVID-19 vaccine (total), plus an option to request up to a further 160 million 
doses (total), to be supplied once a vaccine has proven to be safe and effective.145 
At the time of writing, the EMA considers another application for conditional marketing 
authorisation of COVID-19 vaccine developed by AstraZeneca and Oxford University. The 
CHMP opinion on the marketing authorisation is expected to be released online on the EMA 
website by 29 January, 2021.146 The applications from 5 other pharmaceutical companies are 
expected in due course. They are likely to be processed under the similar conditions, i.e. the 
f́ast-track  ́ authorisation procedure, with the immediate publication of pertinent Product 
information, European public assessment reports and the Risk-management-plans – and with the 
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final clinical trials reports are to be submitted in 2-3- year period.147 It is also most likely that the 
applicants will choose the same strategy of the application kits’ redaction, namely skipping the 
CFREU-related arguments as a ground to invoke Art. 4 of Regulation No. 1049/2001 (a 
´commercially confidental  ́information exception).  
 
ii. Conclusion. In this paper an attempt was made to shed some light on the influence of 
the CFREU provisions on the practice of the Court of Justice of the European Union concerning 
the European Medicines Agency ‘transparency’ policies, as well as the (possible) impact of the 
EU Charter on the development of the Agency extra transparency measures for COVID-19 
vaccines and therapeutics. The author analysed the Court’s usage of Arts. 7, 16, 17, 47 and 42 of 
the EU Charter for interpretation of the ‘commercially confidential’ information in light of the 
key Regulation (EC) No 1049/2001, Regulation (EC) No 726/2004, Regulation 536/2014/EU 
and the implementing EMA Policies 0043 (2010) and 0070 (2014).  
The main arguments presented were that the interpretation of the EU Charter provisions 
within this context, primarily Arts. 7 (‘Respect for private life’), 17 (‘Right to property’) and 47 
(‘The right to an effective remedy’) remains a challenging task  for the Luxembourg Court - due 
to (1) the complexity of the science-based analysis which is to be conducted in light of (2) the 
continuous scrutiny by the European Ombudsman, and (3) a need to counter- balance the 
interests of the pharma enterprises (protection of the business secrets) and the EMA move 
towards the maximum transparency of the MA dossiers (enhancing the research in the EU 
healthcare field).  
In sum, it is possible to agree with Bache, Flear and Hervey who argue that this area of 
EU pharmaceutical law is more focused on ethics and human rights of patients than on a 
straightforward analysis of business risks within the framework of the market for 
pharmaceuticals148 - which seems to a rationale for the restrictive approach chosen. The CJEU 
has elaborated on the way the EMA Policy 0043 shall be applied in the PTC Therapeutics 
International Ltd, MSD Animal Health Innovation GmbH and Pari Pharma GmbH – clearly 
prioritizing the public access to the CTR data over the business interests and fundamental rights 
of the pharma enterprises. The most recent CJEU’s jurisprudence have demonstrated the clear 
demise of the CFREU role as a guardian of the commercial interests of the pharmaceutical 
industry (Intercept Pharma Ltd/Intercept Pharmaceuticals). 
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 It is worth mentioning that the COVID-19 pandemia did not seem to bring any change 
on the ground. To date, no applications were submitted by the pharmaceutical enterprises to the 
EU Court of justice on the basis of the EMA decisions concerning the implemenation of the 
Extra transparency measures for COVID-19 vaccines and therapeutics. At the same time, none of 
the companies attempted to invoke the EU Charter provisions (Arts. 7, 16, 17, 47 and 42 for 
instance) as a ground to block access of the third persons to the application kit submitted to the 
EMA while submitting the application kits for the COVID-19 medicines and vaccines. Neither 
did the CFREU-based arguments appear in the Agency ongoing dialogue with the European 
Ombudsman, or the members of the EU academic community. 
This could be seen both as a response to the extraordinary pandemic situation and the 
unprecedented transparency EMA measures applied under these circumstances as such. 
However, it could also serve as an indication of the (possible) discouragement of the companies 
in usage of the CFREU as a relevant tool to defend their commercial interests, due to the forming 
body of the CJEU’s case-law clearly demonstrating the demise of the EU Charter relevant 
guarantees in the Court’s reasoning. The EMA pertinent t́ransparency  ́policies are not likely to 
be revised in view of Charter-based arguments either. The Agency believes that Regulation No. 
1049/2001 and the pertient CJEU ś case-law specify to a sufficient extent how the key 
fundamental rights to property (Art. 17 CFREU) and one of access to the EU documents (Art. 42 
CFREU) are balanced: there is no general presumption of confidentiality, but the pharmaceutical 
companies still can attempt to explain and justify the confidentiality in a specific case.149 All in 
all, even though the EMA t́ransparency’ policies implementation is clearly aimed at boosting 
the research, including the COVID-related clinical studies, this approach is capable – at the later 
date - of discourgaing the EU and the third country phrmaceutical enterprises from attempts to 
obtain a marketing authorisation for the distribution of the medicinal products in the European 
Union market. 
                                                             
149 Response to ASK-74893 - EMA transparency policies in light of COVID 19, received on 10 December 
2020, p. 5. 
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